Foresite Capital Management IV, LLC - Q1 2020 holdings

$81.1 Million is the total value of Foresite Capital Management IV, LLC's 11 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 100.0% .

 Value Shares↓ Weighting
CBAY ExitCymaBay Therapeutics, Inc.$0-2,315,016
-100.0%
-1.96%
ALEC ExitAlector, Inc.$0-353,462
-100.0%
-2.63%
SIBN ExitSI-BONE, Inc.$0-308,183
-100.0%
-2.86%
OPTN ExitOptiNose, Inc.$0-870,766
-100.0%
-3.46%
ASND ExitAscendis Pharma A/Ssponsored adr$0-68,981
-100.0%
-4.14%
ABUS ExitArbutus BioPharma Corp.$0-3,705,128
-100.0%
-4.44%
MDCO ExitThe Medicines Company$0-403,217
-100.0%
-14.78%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2020-05-28
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
CymaBay Therapeutics, Inc.23Q3 202314.8%
Aclaris Therapeutics, Inc.18Q3 202318.9%
Kura Oncology, Inc.16Q3 202311.7%
Kinnate Biopharma Inc.12Q3 202341.8%
Myokardia, Inc.12Q3 202017.8%
Pharvaris N.V.11Q3 202343.4%
Cytokinetics Incorporated11Q2 202131.6%
Lyell Immunopharma, Inc.10Q3 202329.2%
Insmed Incorporated10Q1 202019.2%
Biohaven Pharmaceutical Holding Company Ltd.9Q1 202014.5%

View Foresite Capital Management IV, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-05-15
42024-04-05
13F-HR2024-02-13
13F-HR2023-11-13
13F-HR2023-08-11
13F-HR2023-05-12
42023-05-10
42023-02-22
13F-HR2023-02-13
13F-HR2022-11-14

View Foresite Capital Management IV, LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export Foresite Capital Management IV, LLC's holdings